1. Pink Sheet
  2. >>Geography

EMA OKs First Digital Outcome As Primary Endpoint In Duchenne Studies

Digital Endpoint Can Be Used As An Alternative To The 6 Minute Walking Test

 
• By Vibha Sharma

A digital outcome for measuring the top walking speed of patients at home that can be captured using wearable devices has been approved by the European Medicines Agency as an alternative primary endpoint in ambulatory Duchenne Muscular Dystrophy studies.

Medicine doctor hands with digital medical interface icons on blur background, Medical technology and healthcare smart watch concept.
A Real-World Digital Endpoint Can More Accurately Reflect The Patient’s Daily Functioning • Source: Shutterstock

The European Medicines Agency has endorsed the use of a digital outcome measure, Stride Velocity 95th Centile (SV95C), as a primary endpoint in superiority studies for ambulant Duchenne Muscular Dystrophy (DMD) patients aged four years and above.

SV95C is a clinical outcome measure that represents the fastest 5% of strides taken by a patient in normal daily life over a period of 180 hours, and can be

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography